search
Antibody-drug conjugates (ADCs) have rapidly become a cornerstone of modern oncology, driven by significant advances in payload-linker technologies. While early ADC programs struggled with stability and manufacturing complexity, recent innovation has drastically improved their clinical viability.
Apr 02, 2026
The development of a new therapy involves multiple stages, from discovery through commercialization. At the center of this process is drug substance manufacturing, where the active pharmaceutical ingredient (API) is produced and refined. Since this stage determines the quality, purity, and scalability of the final therapy, selecting the right development partner can significantly influence project success.
Apr 02, 2026
Low aqueous solubility remains one of the most persistent obstacles in modern drug development programs. Industry studies estimate that roughly 40% of approved drugs and up to 90% of pipeline candidates exhibit poor water solubility. For many compounds, improving solubility is essential to achieving adequate bioavailability and enabling successful clinical and commercial development.
Mar 30, 2026
The pharmaceutical industry develops therapies using a variety of molecular approaches. Two of the most prominent categories are small molecule drugs and biologics, each offering unique advantages depending on the disease target and treatment strategy.
Mar 27, 2026
Cryogenic chemistry plays a critical role in the synthesis of many active pharmaceutical ingredients (APIs). By operating at very low temperatures (typically between -20°C and -90°C), chemists can reduce impurities, improve selectivity, and enhance safety for highly reactive transformations. These advantages make cryogenic reactions a powerful enabler in drug development.
Mar 27, 2026
